18 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
Hokkaido University
Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.
Zhejiang University
Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT).
Novartis Institutes For Biomedical Research
Discovery of Anticancer Agents of Diverse Natural Origin.
University of Illinois At Chicago
Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.
Chinese Academy of Sciences
Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Zhejiang University
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.
University of Kentucky
Structure-Based Design of Selective LONP1 Inhibitors for Probing
Genomics Institute of The Novartis Research Foundation
Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Nanjing Normal University
Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.
Roche Pharma Research and Early Development
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.
Hangzhou Institute of Innovative Medicine
Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators.
Purdue University
Novel Cell-Penetrating Peptide Conjugated Proteasome Inhibitors: Anticancer and Antifungal Investigations.
University of Auckland
Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomycete.
Intermed Discovery Gmbh (Imd)
Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome.
Numazu Bio-Medical Research Institute
Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.
Novartis Pharma